Future studies are needed to determine whether FDA-approved drugs with carbonyl-scavenging properties, such as phenelzine, or pharmacological activators of NRF2, can effectively reduce protein carbonylation and preserve β-cell function in diabetes. The gene discussed is NFE2L2; the disease is diabetes mellitus.